Medindia
Medindia LOGIN REGISTER
Advertisement

Reportlinker Adds Advances in Biopharmaceutical Technology in China

Wednesday, August 25, 2010 Drug News
Advertisement


NEW YORK, Aug. 25 Reportlinker.com announces that a new market research report is available in its catalogue:

Advances in Biopharmaceutical Technology in China
Advertisement

http://www.reportlinker.com/p0265200/Advances-in-Biopharmaceutical-Technology-in-China.html

Every organization has a China strategy, though for many of us it is simply "ignore it." A great opportunity exists in working with China and implementing an effective company strategy. However, winning in Asia in the new millennium will require fundamental changes in partnerships between western and Asian companies. Every company faces the question "What should our China strategy be?" But to neglect China is to forego opportunities to gain efficiency in most of the things we are trying to do. China provides opportunities that allow us to do different things and not just do things differently.
Advertisement

This volume provides an overview of the biopharmaceutical industry, and the state of technology. It will help the reader understand general business practice in China, analyze business opportunities and in identifying potential partners for working in China. It provides a ready reference for all aspects of the world of biopharmaceuticals in China, including general understanding, detailed technical and business descriptions, and detailed information on all types of organizations involved in biopharmaceuticals in China, whether they be companies (state owned or privately owned), universities, or government institutions.

By the Numbers:

-46 Internationally Recognized Authors

-23 Peer-Reviewed Chapters

-900 Pages

-15 Translated Chapters and Case Studies

-19 Case Studies and China Briefs

-380 References

-Over 2,000 Index Entries

-Current Listing of over 2,000 Chinese Biopharmaceuticals and Diagnostics (database)

Abstracts

Chapter 1: Introduction: A China Biopharmaceuticals Strategy

Chapter 2: An Overview of Biopharmaceutical Developments in China

Chapter 3: China's Healthcare System and the Demand for Biopharmaceutical Products

Chapter 4: China Pharmaceuticals Market Situation 2006

Chapter 5: Biopharmaceutical Strategy in China: An Analysis of Innovation, Financing Policies, Talent, and Strategic Considerations Through 2010 (11th 5-year Plan)

Chapter 6: Biopharmaceuticals in China: A Market, Import/Export, and Financial Review

Chapter 7: Pharmacy and Drug Administration in China

Chapter 8: Regulatory Requirements Applicable to Clinical Trials in China

Chapter 9: FDA Requirements Applicable to Testing and Manufacturing Pharmaceutical Products in China for the U. S. Market

Chapter 10: Protection and Enforcement of Biopharmaceutical Intellectual Property Rights in China - A Rapidly Evolving System

Chapter 11: Biopharmaceutical Industry Venture Capital Investment in Mainland China

Chapter 12: Drug Discovery and Development Partnerships: Outsourcing and Partnering with China

Chapter 13: Doing Business in China

Chapter 14: Current Status and Future Prospect of Biogeneric Companies in China

Chapter 15: Biopharmaceutical Products in China

Chapter 16: Chinese Bioindustry Parks: Evolution and Growth

Chapter 17: Organizations in China involved in Biopharmaceutical Research and Manufacturing

Chapter 18: Life Science and Health Science Education in China

Chapter 19: Biopharmaceutical Research Collaboration between Western and Chinese Life Science Organization: A Guide to Prospective Partnership

Chapter 20: Industrial Technology Developments for Chinese Biopharmaceuticals

Chapter 21: Therapeutic Proteins in China

Chapter 22: Vaccines in China: Status of the Chinese Vaccine Industry

Chapter 23: Biotechnology and Analytical Methods in the Modernization of Traditional Chinese Herbal Medicine

Chapter 24: CHINA Briefs (Miscellaneous Articles)

Author Organizations:

Arnold & Porter, LLP

Beijing BaiAo Pharmaceutical Co., Ltd.

Beijing WanTai Biological Product Co., Ltd.

Business Monitor International

CanBiotech

Chemical Industry Press (China)

Chiltern International

China National Center for Biotechnology Development

China National Development and Reform Commission, Chinese Academy of Macroeconomic Research

China National Development and Reform Commission, High-Tech Industry Department

China Pharmaceutical University, College of Life Science and Technology

Chinese Academy of Social Sciences (CASS), Institute of World Economics and Politics

Chinese Ministry of Science and Technology, National Advisory Committee for "863 High Technology Program"

Deacons Hong Kong

Fudan University, International Finance

MMD Pharmahe

Nanjing University, Department of Biochemistry

National Institutes of Health (NIH), Office of Technology Transfer

National Vaccine & Serum Institute

Perkins Coie LLP (Los Angeles)

Shandong University

Shanghai CITIC GuoJian Pharmaceutical Co., Ltd.

Shanghai Tongji University, Investment Research Institute

Shanghai Venture Capital Corporation

Shenzhen Neptunus Interlong Biotech Co., Ltd

Shenzhen ZYPH Intelligence Co., Ltd.

Sichuan University, West China School of Pharmacy

Strategic Manufacturing Worldwide, Inc.

TechNova Medical Services

Tsinghua University, School of Medicine

3DBGlobal, Inc.

To order this report:

Biopharmaceutical Industry: Advances in Biopharmaceutical Technology in China

Biopharmaceutical Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Contact Nicolas Bombourg Reportlinker Email: [email protected] US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close